Skip to content

MED COSTE NEUPREZ

Active Private limited companyfounded 2016active for 10 yearsAvenue Blonden 64/81, 4000 LiègeKBO/BCE: BE 0649.790.033

Lifetime

10 annual accounts with figures on one time axis
peak of €698,592 in 2025
€698,592▲ 31.5%
peak of €524,955 in 2025
€524,955▲ 36.2%
peak of €375,052 in 2021
€18,642▼ 5.3%
€505,005▲ 0.9%
Board2 names since 2016
2 directors and 1 other
Documentsfilings and deeds
18-03-2026135 days before the deadline
2025micro format
Gross margin from €531,361 to €698,592Result from €385,565 to €524,955Dividend €526,000Cash from €61,579 to €127,607

Key points

from the 2025 annual accounts

Equity

€18,642 from €375,052 in 2021

Equity fell by 95% in 4 years.

Result

€524,955 ▲ 36.2%
€386,0002024€525,0002025

The result rose in 2025 from €385,565 to €524,955.

Debts

€505,005 96% of the balance sheet
Financial debts 0%Suppliers 13%Taxes and wages 5%Other 82%

Of this, €502,275 falls due within a year.

Investments

€24,545 1.7 times depreciation
20212022202320242025

Green is investment, beige is depreciation.

Filings

10 annual accounts 1 late
AprilJune31 JulyOctober20202025

The 2019 accounts came 17 days late. The other nine were filed on time.

Position in the sector

3.6%

Lower solvency than 91% of companies in human health. The sector median is 63.0%, over 21,385 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 538 companies had the same profile as MED COSTE NEUPREZ has now. Each dot stands for 2 companies, two years later.

95.7%
were still trading
3.5%
stopped another way
0.7%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency under 10%
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 538 companies, not a prediction for MED COSTE NEUPREZ. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 08-03-2016
Director, since 08-03-2016
  • 240 sharesdeed of 14-03-2016
  • 60 sharesdeed of 14-03-2016
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0649790033
2 directors reappointed (director) and (director) · acts as permanent representative · “L'exercice de la médecine, gynécologies, obstétrique, médecine physique, médecine du sport, la physiothérapie…” (deed in French) · General meeting of 26-07-2023 · Gazette deed
Incorporation Founding capital of €18,600, 300 shares, €6,200 paid up · Founded by and · (manager) and (manager) appointed · published on 14-03-2016 · Gazette deed
First establishment Quai Marcellis 33, Liège
All 18 events

Comparable companies

same main activity, similar in size and age
Company
MED COSTE NEUPREZ Liège €523,646 €698,592 3.6% -
DRGH Lanaken €541,032 €717,517 69.7% -
Dr. Steven Heireman Kortrijk €524,577 €666,156 3.5% -
DRS. CAEKEBEKE EN D'HAESE Antwerp €492,037 €683,211 0.0% -
Dr. Caroline VENSTERMANS Edegem €514,364 €645,952 94.4% -
Dr. Anne-Sophie Vliegen - Radioloog Hasselt €548,254 €603,727 25.2% -
Dr. A. Vanden Bulcke Roeselare €514,747 €617,580 92.7% -

These companies have the same main activity as MED COSTE NEUPREZ: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €492,000 and €548,000, founded between 2015 and 2017.

Official details

Source: KBO
Status
Active since 10-03-2016Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.250.863.3234020 Liège, since 10-03-2016
Financial year end
31 December
Peppol
Reachable since 27-10-2025
Company details

Annual accounts 2025

≈ €1.1mestimated
€523,646▲ 0.7%
Filing
Filed on 18-03-2026, 135 days before the end of the filing period
Financials

Insights on MED COSTE NEUPREZ

MED COSTE NEUPREZ files the micro format. That format states no turnover. The gross margin rose from €104,431 in 2016 to €698,592 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about MED COSTE NEUPREZ

What is the company number of MED COSTE NEUPREZ?
The company number of MED COSTE NEUPREZ is 0649.790.033. The VAT number is the same number with BE in front: BE 0649.790.033.
Where is MED COSTE NEUPREZ based?
The registered office is at Avenue Blonden 64/81, 4000 Liège.Company details
What does MED COSTE NEUPREZ do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of MED COSTE NEUPREZ?
MED COSTE NEUPREZ is a private limited company (BV).
When was MED COSTE NEUPREZ founded?
MED COSTE NEUPREZ was founded on 10-03-2016.
Is MED COSTE NEUPREZ still active?
Yes, MED COSTE NEUPREZ is an active enterprise in the KBO register.
What is the turnover of MED COSTE NEUPREZ?
The turnover in financial year 2025 is about €1.1m. This figure is estimated from the gross margin of €698,592 and 31 comparable companies (NACE 86220). It probably lies between €930,000 and €1.5m.Financials
Is MED COSTE NEUPREZ profitable?
In financial year 2025, MED COSTE NEUPREZ made a profit of €524,955.
Where can I find the annual accounts of MED COSTE NEUPREZ?
MED COSTE NEUPREZ filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of MED COSTE NEUPREZ due?
MED COSTE NEUPREZ must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.